alzheon, Author at Alzheon | Preserving Future Memories - Page 4 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 204 blog entries.

13 Sep, 2023

Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

alzheon2024-08-05T19:59:29-04:00September 13th, 2023|

16 Jul, 2023

AAIC: A Pill to Slow Down Alzheimer’s Is About Two Years Away

alzheon2023-07-18T10:41:12-04:00July 16th, 2023|

13 Jul, 2023

Venture Capitalists Fund New Generation of Alzheimer’s Drugs

alzheon2024-06-06T17:58:07-04:00July 13th, 2023|Tags: WSJ|

11 Jul, 2023

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at Alzheimer’s Association International Conference in Amsterdam

alzheon2024-08-12T09:43:10-04:00July 11th, 2023|

27 Jun, 2023

Advances in AD Treatments

alzheon2023-07-20T10:28:14-04:00June 27th, 2023|

27 Jun, 2023

Part 2: APOE Genotyping in Clinical Practice: Pros and Cons

alzheon2023-07-20T10:30:08-04:00June 27th, 2023|

27 Jun, 2023

Part 1: The Role of APOE Genotyping in Alzheimer’s Disease Risk Stratification

alzheon2023-07-20T10:29:35-04:00June 27th, 2023|

27 Jun, 2023

Unprecedented Reduction in Key Alzheimer’s Biomarker for Patients Treated With ALZ-801

alzheon2023-07-28T10:07:13-04:00June 27th, 2023|

27 Jun, 2023

A First of Its Kind, ALZ-801 Aims To Preserve Memories, Save Lives: An Exclusive Interview with Dr. Martin Tolar

alzheon2023-07-27T17:26:57-04:00June 27th, 2023|

27 Jun, 2023

The Science Behind the Drug That May Stop Alzheimer’s Disease in Its Tracks

alzheon2023-07-17T13:26:16-04:00June 27th, 2023|